
- Telehealth Visits
- Insurance plan information
- Provider Type: Physician

Andrew H. Ko, MD
Medical Oncology (Gastrointestinal Cancer)- Telehealth Visits
- Insurance plan information
- Provider Type: Physician



Andrew H. Ko, MD
Medical Oncology (Gastrointestinal Cancer)On this page
About me
Dr. Andrew H. Ko is a specialist in digestive system cancers. He provides compassionate and individualized care for patients with cancers of the pancreas, stomach and esophagus.
In research, Ko has long been active in developing and evaluating new treatments for gastrointestinal cancers, including molecularly targeted agents and immune-based therapies.
Ko earned an undergraduate degree in applied mathematics and biology at Brown University. He earned his medical degree at the Johns Hopkins University School of Medicine. He completed a residency in internal medicine at Beth Israel Deaconess Medical Center, an affiliate of Harvard Medical School, and completed a fellowship in medical oncology at Stanford University. He joined UCSF in 2001.
Education & training
Board certification
- Medical Oncology, American Board of Internal Med/Medical Oncology
Fellowship
- Medical Oncology & Hematology, Stanford University Medical Center-GME
Residency
- Internal Medicine, Beth Israel Deaconess Medical Center - East Campus
Internship
- Internal Medicine, Beth Israel Deaconess Medical Center - East Campus
Degree
- MD, Johns Hopkins University School of Medicine
Academic title
- Clinical Professor
My expertise
Locations
My research
Clinical trials
A Study of 177Lu-FAP-2286 in Advanced Solid TumorsOpens in a new window
Recruiting
To evaluate the safety and tolerability of [177Lu]Lu FAP 2286 and determine the RP2DStudy of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)Opens in a new window
Recruiting
DFS defined as the time from randomization until disease recurrence or death from any cause, whichever occurs first. Recurrence is per response evaluation crit...Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaOpens in a new window
Recruiting
Comparison of PFS of daraxonrasib + gemcitabine and nab-paclitaxel (Arm B) versus gemcitabine and nab-paclitaxel (Arm C). PFS is defined as the time from rando...
Publications
Showing 1-6 of 60 reviews
- September 17, 20265 out of 5 Stars
Dr Ko is wonderful! He explained everything well. Care about his patient. Very knowledgeable.
- September 15, 20265 out of 5 Stars
Dr. Ko is an amazing doctor who has the care and compassion that patients need who face life threatening diseases. He listens carefully and then takes his time responding.
- September 4, 20265 out of 5 Stars
Dr Andrew Ko was amazing in every respect. I felt heard, valued and nurtured.
- August 25, 20265 out of 5 Stars
Dr. Ko was excellent in every single way. From explaining my condition to answering difficult questions, to the compassion that he showed.
- August 23, 20265 out of 5 Stars
Dr Ko is wonderful!!!!
- August 13, 20265 out of 5 Stars
Exceptional service and clear messages.
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.
The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.